Pharmaceutical company Lilly has issued a warning about potential health risks associated with compounded tirzepatide mixed with vitamin B12. The company’s testing revealed significant levels of an impurity resulting from a chemical reaction between tirzepatide and B12. This impurity raises concerns due to unknown effects on human health and interactions with GLP-1 and GIP receptors.
Lilly emphasized that tirzepatide has never been studied in combination with B12. The company has notified the U.S. Food and Drug Administration (FDA) about these findings and recommends that patients using these untested products consult their physicians for alternative treatments. The FDA has previously warned about the risks of compounded drugs, which are not subject to the same safety and quality reviews as FDA-approved medicines.
The impurity discovery highlights the risks of mixing untested additives with complex molecules like tirzepatide without rigorous testing and FDA approval. Lilly’s findings have prompted calls for a recall of all compounded tirzepatide products combined with untested additives such as B12.
The FDA has recently pledged to take action against companies marketing illegal copycat drugs. Despite previous legal actions and safety warnings, some entities continue to compound tirzepatide, claiming to offer “personalized” versions by adding untested additives. Lilly’s warning underscores the importance of relying on FDA-approved medications for patient safety.
Recent Comments